Moleculin Reports First Quarter 2023 Financial Results

– Continued clinical and operational execution across ongoing development programs with growing body of positive preclinical and clinical data – Sufficient capital to fund operations into the third quarter of 2024 – Company to host conference call and webcast today at 8:30 AM ET HOUSTON, May 11, 2023 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” … Read more